Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters








Database
Language
Publication year range
1.
J Leukoc Biol ; 116(4): 876-889, 2024 Oct 01.
Article in English | MEDLINE | ID: mdl-38798090

ABSTRACT

The CCL2/CC chemokine receptor 2 axis plays key roles in the pathogenesis of HIV-1 infection. We previously reported that exposure of monocyte-derived macrophages to CCL2 neutralizing antibody (αCCL2 Ab) restricted HIV-1 replication at postentry steps of the viral life cycle. This effect was associated with induction of transcripts coding for innate antiviral proteins, including APOBEC3A and RSAD2. This study aimed at identifying the signaling pathways involved in induction of these factors by CCL2 blocking in monocyte-derived macrophages. Through a combination of pharmacologic inhibition, quantitative reverse transcription polymerase chain reaction, Western blotting, and confocal laser-scanning microscopy, we demonstrated that CCL2 neutralization activates the canonical NF-κB and JAK/STAT pathways, as assessed by time-dependent phosphorylation of IκB, STAT1, and STAT3 and p65 nuclear translocation. Furthermore, pharmacologic inhibition of IκB kinase and JAKs strongly reduced APOBEC3A and RSAD2 transcript accumulation elicited by αCCL2 Ab treatment. Interestingly, exposure of monocyte-derived macrophages to αCCL2 Ab resulted in induction of IL-6 family cytokines, and interference with glycoprotein 130, the common signal-transducing receptor subunit shared by these cytokines, inhibited APOBEC3A and RSAD2 upregulation triggered by CCL2 neutralization. These results provide novel insights into the signal transduction pathways underlying the activation of innate responses triggered by CCL2 neutralization in macrophages. Since this response was found to be associated with protective antiviral effects, the new findings may help design innovative therapeutic approaches targeting CCL2 to strengthen host innate immunity.


Subject(s)
Chemokine CCL2 , Cytidine Deaminase , Cytokine Receptor gp130 , Janus Kinases , Macrophages , NF-kappa B , Signal Transduction , Humans , Macrophages/immunology , Macrophages/metabolism , Macrophages/virology , NF-kappa B/metabolism , Janus Kinases/metabolism , Chemokine CCL2/metabolism , Chemokine CCL2/genetics , Chemokine CCL2/immunology , Cytidine Deaminase/genetics , Cytidine Deaminase/metabolism , Cytokine Receptor gp130/metabolism , Cytokine Receptor gp130/genetics , Antibodies, Neutralizing/pharmacology , Antibodies, Neutralizing/immunology , Proteins/metabolism , Proteins/genetics , STAT Transcription Factors/metabolism , Cells, Cultured
2.
Front Immunol ; 11: 2129, 2020.
Article in English | MEDLINE | ID: mdl-33072075

ABSTRACT

Macrophages are key targets of human immunodeficiency virus type 1 (HIV-1) infection and main producers of the proinflammatory chemokine CC chemokine ligand 2 (CCL2), whose expression is induced by HIV-1 both in vitro and in vivo. We previously found that CCL2 neutralization in monocyte-derived macrophages (MDMs) strongly inhibited HIV-1 replication affecting post-entry steps of the viral life cycle. Here, we used RNA-sequencing to deeply characterize the cellular factors and pathways modulated by CCL2 blocking in MDMs and involved in HIV-1 replication restriction. We report that exposure to CCL2 neutralizing antibody profoundly affected the MDM transcriptome. Functional annotation clustering of up-regulated genes identified two clusters enriched for antiviral defense and immune response pathways, comprising several interferon-stimulated, and restriction factor coding genes. Transcripts in the clusters were enriched for RELA and NFKB1 targets, suggesting the activation of the canonical nuclear factor κB pathway as part of a regulatory network involving miR-155 up-regulation. Furthermore, while HIV-1 infection caused small changes to the MDM transcriptome, with no evidence of host defense gene expression and type I interferon signature, CCL2 blocking enabled the activation of a strong host innate response in infected macrophage cultures, and potently inhibited viral genes expression. Notably, an inverse correlation was found between levels of viral transcripts and of the restriction factors APOBEC3A (apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 A), ISG15, and MX1. These findings highlight an association between activation of innate immune pathways and HIV-1 restriction upon CCL2 blocking and identify this chemokine as an endogenous factor contributing to the defective macrophage response to HIV-1. Therapeutic targeting of CCL2 may thus strengthen host innate immunity and restrict HIV-1 replication.


Subject(s)
Antibodies, Neutralizing/pharmacology , Chemokine CCL2/pharmacology , Gene Expression Profiling , Gene Expression Regulation, Viral/drug effects , HIV-1/genetics , Immunity, Innate , Macrophages/metabolism , Antibodies, Neutralizing/immunology , Antibody Specificity , Cells, Cultured , Chemokine CCL2/antagonists & inhibitors , Chemokine CCL2/immunology , Cytidine Deaminase/physiology , Datasets as Topic , Humans , Macrophages/drug effects , Macrophages/immunology , Macrophages/virology , MicroRNAs/biosynthesis , MicroRNAs/genetics , Molecular Sequence Annotation , NF-kappa B/metabolism , Proteins/physiology , RNA, Viral/biosynthesis , RNA, Viral/genetics , RNA-Seq , Real-Time Polymerase Chain Reaction , Virus Latency , Virus Replication
3.
Front Immunol ; 9: 1839, 2018.
Article in English | MEDLINE | ID: mdl-30135687

ABSTRACT

Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family members are cytidine deaminases that play crucial roles in innate responses to retrovirus infection. The mechanisms by which some of these enzymes restrict human immunodeficiency virus type 1 (HIV-1) replication have been extensively investigated in vitro. However, little is known regarding how APOBEC3 proteins affect the pathogenesis of HIV-1 infection in vivo and how antiretroviral therapy influences their expression. In this work, a longitudinal analysis was performed to evaluate APOBEC3G/3A expression in peripheral blood mononuclear cells of antiretroviral-naive HIV-1-infected individuals treated with cenicriviroc (CVC) or efavirenz (EFV) at baseline and 4, 12, 24, and 48 weeks post-treatment follow-up. While APOBEC3G expression was unaffected by therapy, APOBEC3A levels increased in CVC but not EFV arm at week 48 of treatment. APOBEC3G expression correlated directly with CD4+ cell count and CD4+/CD8+ cell ratio, whereas APOBEC3A levels inversely correlated with plasma soluble CD14. These findings suggest that higher APOBEC3G/3A levels may be associated with protective effects against HIV-1 disease progression and chronic inflammation and warrant further studies.


Subject(s)
APOBEC-3G Deaminase/genetics , Cytidine Deaminase/genetics , Gene Expression Regulation , HIV Infections/genetics , HIV Infections/virology , HIV-1 , Proteins/genetics , APOBEC-3G Deaminase/metabolism , Adult , Alkynes , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Benzoxazines/therapeutic use , CD4 Lymphocyte Count , Cyclopropanes , Cytidine Deaminase/metabolism , Disease Progression , Female , Gene Expression Regulation/drug effects , HIV Infections/drug therapy , HIV Infections/immunology , HIV-1/drug effects , Humans , Imidazoles/therapeutic use , Male , Middle Aged , Proteins/metabolism , Sulfoxides , Treatment Outcome , Viral Load , Young Adult
4.
ChemSusChem ; 5(6): 1080-5, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22581429

ABSTRACT

Microbial biocathodes allow converting and storing electricity produced from renewable sources in chemical fuels (e.g., H(2) ) and are, therefore, attracting considerable attention as alternative catalysts to more expensive and less available noble metals (notably Pt). Microbial biocathodes for H(2) production rely on the ability of hydrogenase-possessing microorganisms to catalyze proton reduction, with a solid electrode serving as direct electron donor. This study provides new chemical and electrochemical data on the bioelectrocatalytic activity of Desulfovibrio species. A combination of chronoamperometry, cyclic voltammetry, and impedance spectroscopy tests were used to assess the performance of the H(2) -producing microbial biocathode and to shed light on the involved electron transfer mechanisms. Cells attached onto a graphite electrode were found to catalyze H(2) production for cathode potentials more reducing than -900 mV vs. standard hydrogen electrode. The highest obtained H(2) production was 8 mmol L(-1) per day, with a Coulombic efficiency close to 100 %. The electrochemical performance of the biocathode changed over time probably due to the occurrence of enzyme activation processes induced by extended electrode polarization. Remarkably, H(2) (at least up to 20 % v/v) was not found to significantly inhibit its own production.


Subject(s)
Bioelectric Energy Sources/microbiology , Desulfovibrio/metabolism , Hydrogen/chemistry , Catalysis , Electric Impedance , Electrochemistry , Electrodes/microbiology , Graphite
SELECTION OF CITATIONS
SEARCH DETAIL